Among the myeloproliferative diseases, myelofibrosis is a widely heterogeneous entity
characterized by a highly variable prognosis. In this context, several prognostic models have …

Hematopoietic stem cell transplantation (HCT) represents a curative treatment option for
certain malignant and nonmalignant hematological diseases. Conditioning regimens before …

Hematopoietic cell transplantation is an established curative treatment option for various
hematological malignant, and non-malignant diseases. However, the success of HCT is still …

Introduction The approach to myelofibrosis (MF) has been revolutionized in recent years,
overcoming the traditional therapies, often not very effective. Janus kinase inhibitors (JAKi …

Plasma biomarkers of endothelial dysfunction have been postulated for the diagnosis and
prognosis of acute graft-versus-host disease (aGVHD). However, their use is not validated in …

Transplant-associated thrombotic microangiopathy (TA-TMA) is an endotheliopathy
complicating up to 30% of allogeneic hematopoietic stem cell transplants (alloHSCT) …

Haematopoietic stem cell transplantation is a mainstay of therapy for numerous malignant
and nonmalignant diseases. Endothelial activation and dysfunction occur after stem cell …

High titer of donor-specific antibodies (DSAs) increases the risk of graft rejection after
mismatched related hematopoietic cell transplantation (HCT). There are no data regarding …

Background Transplantation of CD34+ hematopoietic stem and progenitor cells (HSPC) into
immunodeficient mice is an established method to generate humanized mice harbouring a …

Introduction Hematopoietic stem cell transplantation (HSCT) is associated with immune
complications and endothelial dysfunction due to intricate donor-recipient interactions …